← Back to Home

Keeping CAR T Cells in Bone Marrow Longer: New Receptor Shows Promise in Mouse Cancer Models

Beyond recognizing cancer cells, cell therapies also need to sustain their activity. A Moffitt team used RANKL in the bone environment to provide supplementary stimulation to γδ CAR T cells, improving their persistence in mouse bone marrow. Whether this can deliver more durable benefits in humans remains to be verified.

By SURL BioNews

When fighting cancer in bone, immune cells may be able to recognize and attack tumors without remaining at the site for long. A research team at Moffitt Cancer Center in the United States added an engineered receptor to γδ (gamma-delta) CAR T cells and observed increased cell persistence in bone marrow in a mouse model of prostate cancer with bone metastases. The findings offer clues to extending the activity of cell therapies, but do not yet establish better anticancer efficacy.

The study was published in *Cellular & Molecular Immunology* on September 30, and Moffitt presented the findings on October 20. The team first equipped αβ and γδ T cells with the same second-generation CAR recognizing prostate stem cell antigen (PSCA), allowing them to compare how the cells themselves affect the engineered receptor’s function. The two types had similar abilities to kill cancer cells, but their signaling and metabolic responses after activation differed markedly.

The researchers identified 307 protein phosphorylation sites that differed in abundance. Functional experiments confirmed that γδ CAR T cells had lower glycolytic and oxidative phosphorylation capacities, as well as weaker AP-1 signaling associated with cell activation. This suggests that the same CAR design may not perform identically in different T-cell types; receptor engineering may need to be tailored to the cell type.

The team therefore designed an additional receptor called SWITCH27, combining a RANKL-recognizing component with CD27 costimulatory signaling. RANKL is present in bone and the tumor microenvironment, and the researchers hoped to use it to provide supplementary stimulation to γδ CAR T cells arriving at these sites. This receptor provides costimulation, while the original CAR remains responsible for recognizing cancer cells. Experiments showed that SWITCH27 could enhance AP-1-related activity.

In the model of prostate cancer with bone metastases, both the original γδ CAR T cells and those equipped with SWITCH27 controlled tumor burden. At the experimental endpoint, however, more γδ T cells could be recovered from the bone marrow in the SWITCH27 group. Another mouse model of multiple myeloma also showed a trend toward improved persistence. These results support further investigation of sustained activity, but have not yet demonstrated that the additional receptor provides stronger tumor control.

The study also explored another route to improvement: modifying metabolism. γδ T cells had higher levels of the protein TXNIP. After reducing its activity through drug inhibition or CRISPR gene editing, the team observed improvements in some measures of metabolism, CAR expression, and immune signaling molecule secretion. This is a different engineering strategy from adding a receptor. Whether the approaches can eventually be integrated into a stable, safe cell product still requires step-by-step validation.

The current evidence comes from experiments with human cells and mouse models; there is no evidence yet of therapeutic benefit in humans. More cells in bone marrow also does not mean that patients will achieve longer disease control. The paper also disclosed that Miguel G. Fontela, Patrick Hwu, and Daniel Abate-Daga are involved in patent applications filed by Moffitt for related technologies. The key next steps are to determine whether increased persistence also improves efficacy, and whether cells subjected to sustained stimulation can maintain an acceptable safety profile.

References

  1. Moffitt Cancer Center via Phys.org
  2. PubMed — Cellular & Molecular Immunology